As of November 8, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Research Alliance Corporation IV. The largest reported stake is Research Alliance Holdings IV LLC's, at 17%. 5 filings are on record since July 20, 2026 (Schedule 13D, July 21, 2026).
Sell to companies like Research Alliance Corporation IV? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Research Alliance Holdings IV LLC · Sole voting: 0 · Shared voting: 1,538,529 · Sole dispositive: 0 · Shared dispositive: 1,538,529 · SCHEDULE 13D, 2026-07-21
- · Reporting person: Trails Edge Capital Partners, LP · Sole voting: 500,000 · Shared voting: 0 · Sole dispositive: 500,000 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-21
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 700,000 · Sole dispositive: 0 · Shared dispositive: 700,000 · SCHEDULE 13G, 2026-07-20
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 262,376 · Sole dispositive: 0 · Shared dispositive: 262,376 · SCHEDULE 13G, 2026-07-20
- · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 500,000 · Sole dispositive: 0 · Shared dispositive: 500,000 · SCHEDULE 13G, 2026-07-20
Research Alliance Corporation IV has 5 Schedule 13D or 13G filings on record since 2026-07-20. 5 holders' latest filing reports 5% or more of class a ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Research Alliance Holdings IV LLC | 17% | 1,538,529 | SCHEDULE 13D, 2026-07-21 | 2026-07-14 |
| Perceptive Advisors LLC | 7.7% | 700,000 | SCHEDULE 13G, 2026-07-20 | 2026-07-13 |
| Bvf Partners L P | 6.4% | 500,000 | SCHEDULE 13G, 2026-07-20 | 2026-07-13 |
| Commodore Capital LP | 5.5% | 500,000 | SCHEDULE 13G, 2026-07-20 | 2026-07-13 |
| Trails Edge Capital Partners, LP | 5.5% | 500,000 | SCHEDULE 13G, 2026-07-21 | 2026-07-14 |
Holding shares or following this stake? See who's behind Research Alliance Corporation IV and the warning signs.
Free to see. No signup.
Keep reading
More on Research Alliance Corporation IV and the records around it.
Companies that share a holder
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Research Alliance Corporation IV
Get an email when Research Alliance Corporation IV files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Research Alliance Corporation IV?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Research Alliance Corporation IV: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Research Alliance Corporation IV covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Research Alliance Holdings IV LLC | 0 | 1,538,529 | 0 | 1,538,529 | SCHEDULE 13D, 2026-07-21 |
| Matthew Hammond | 0 | 1,538,529 | 0 | 1,538,529 | SCHEDULE 13D, 2026-07-21 |
| Perceptive Advisors LLC | 0 | 700,000 | 0 | 700,000 | SCHEDULE 13G, 2026-07-20 |
| Joseph Edelman | 0 | 700,000 | 0 | 700,000 | SCHEDULE 13G, 2026-07-20 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 700,000 | 0 | 700,000 | SCHEDULE 13G, 2026-07-20 |
| Biotechnology Value Fund L P | 0 | 262,376 | 0 | 262,376 | SCHEDULE 13G, 2026-07-20 |
| Bvf I Gp LLC | 0 | 262,376 | 0 | 262,376 | SCHEDULE 13G, 2026-07-20 |
| Biotechnology Value Fund Ii LP | 0 | 196,800 | 0 | 196,800 | SCHEDULE 13G, 2026-07-20 |
| Bvf Ii Gp LLC | 0 | 196,800 | 0 | 196,800 | SCHEDULE 13G, 2026-07-20 |
| Biotechnology Value Trading Fund OS LP | 0 | 32,968 | 0 | 32,968 | SCHEDULE 13G, 2026-07-20 |
| BVF Partners OS Ltd. | 0 | 32,968 | 0 | 32,968 | SCHEDULE 13G, 2026-07-20 |
| Bvf Gp Holdings LLC | 0 | 459,176 | 0 | 459,176 | SCHEDULE 13G, 2026-07-20 |
| Bvf Partners L P | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Bvf Inc | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Lampert Mark N | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Commodore Capital LP | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Commodore Capital Master LP | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Robert Egen Atkinson | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Michael Kramarz | 0 | 500,000 | 0 | 500,000 | SCHEDULE 13G, 2026-07-20 |
| Trails Edge Capital Partners, LP | 500,000 | 0 | 500,000 | 0 | SCHEDULE 13G, 2026-07-21 |
| Trails Edge Biotechnology Master Fund, LP | 500,000 | 0 | 500,000 | 0 | SCHEDULE 13G, 2026-07-21 |
| Ortav Yehudai | 500,000 | 0 | 500,000 | 0 | SCHEDULE 13G, 2026-07-21 |
The latest filing identifies Research Alliance Corporation IV by CUSIP G75228109 and gives its principal executive office as 600 Fifth Avenue, 23rd Floor, New York, NY 10020 (SCHEDULE 13D, 2026-07-21).
What the percentages are based on
The following percentages are based on 7,775,000 Shares outstanding (which excludes the Issuer's Class B Ordinary Shares) as of the close of the Issuer's underwritten public offering as reported in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 13, 2026.Bvf Partners L P, SCHEDULE 13G, 2026-07-20
Source of funds (Item 3)
On April 7, 2026, RA Holdings IV paid $25,000 to cover certain expenses on the Issuer's behalf in exchange for the issuance of 1,014,706 Class B ordinary shares, or approximately $0.02 per share. The number of Class B ordinary shares issued was determined based on the expectation that the Class B ordinary shares would represent 15% of the Issuer's issued and outstanding ordinary shares (excluding the Private Placement Shares, as defined below) upon the consummation of the Issuer's initial public offering (the "IPO").Research Alliance Holdings IV LLC, SCHEDULE 13D, 2026-07-21
Purpose of Transaction (Item 4)
Research Alliance Holdings IV LLC
RA Holdings IV acquired the Class A ordinary shares and Class B ordinary shares reported herein for investment purposes. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time (including following the completion of the Issuer's initial business combination), acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving from development-stage or commercial programs of the Issuer, or dispose of Issuer securities they beneficially own, on the open market or in private transactions or otherwise (including by means of 10b5-1 programs), consistent with their investment purposes and in amounts, on such terms and at such times as to be determined by the Reporting Persons based upon a number of factors, including, without limitation, their ongoing assessment of the Issuer's business prospects, the availability of Issuer securities at prices that would make the purchase or sale of such securities desirable, prevailing market conditions, the availability of other investment opportunities, and/or other considerations. The Class A ordinary shares and Class B ordinary shares held by RA Holdings IV are subject to certain lock-up restrictions as further described in …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-21; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-07-20 | Bvf Partners L P | 6.4% | SCHEDULE 13G |
| 2026-07-20 | Perceptive Advisors LLC | 7.7% | SCHEDULE 13G |
| 2026-07-20 | Commodore Capital LP | 5.5% | SCHEDULE 13G |
| 2026-07-21 | Trails Edge Capital Partners, LP | 5.5% | SCHEDULE 13G |
| 2026-07-21 | Research Alliance Holdings IV LLC | 17% | SCHEDULE 13D |
Questions about who owns Research Alliance Corporation IV
Who owns Research Alliance Corporation IV?
On this page, 5 holders' latest ownership filings report 5% or more of Research Alliance Corporation IV: Research Alliance Holdings IV LLC (17%, Schedule 13D, filed 2026-07-21), Perceptive Advisors LLC (7.7%, Schedule 13G, filed 2026-07-20), Bvf Partners L P (6.4%, Schedule 13G, filed 2026-07-20), Commodore Capital LP (5.5%, Schedule 13G, filed 2026-07-20) and Trails Edge Capital Partners, LP (5.5%, Schedule 13G, filed 2026-07-21).
Who are the largest shareholders of Research Alliance Corporation IV?
By the share each holder's latest filing reports, the largest holders of Research Alliance Corporation IV on this page are Research Alliance Holdings IV LLC (17%), Perceptive Advisors LLC (7.7%) and Bvf Partners L P (6.4%).
When did Research Alliance Holdings IV LLC buy into Research Alliance Corporation IV?
The filings give report dates, not purchase dates. The earliest filing from Research Alliance Holdings IV LLC on this page is the Schedule 13D, filed 2026-07-21, reporting 17%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Research Alliance Corporation IV
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 14, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 13, 2026 | IPO filing, Form 424B4 | $10 a share | IPO filings | Source |
| July 8, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 8, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Research Alliance Corporation IV. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.